Despite Exubera Scare, Mannkind Marches On
This article was originally published in The Pink Sheet Daily
Executive Summary
Fair or not, “cancer” word repels patients and doctors, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
MannKind Breathing Easier After FDA Diabetes Safety Guidance
Trials for inhaled insulin Afresa were already designed to satisfy new cardiovascular risk guidelines, firm says.